In this episode, we highlight and address the disproportionate burden of rheumatic diseases and COVID-19 in ethnic minorities and the gender disparities observed in rheumatology care.
Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus.
Researchers determined whether SLE could have an early effect on peripheral nerve function before the development of electrophysiologic abnormalities.
Researchers evaluated EULAR/ERA-EDTA response to therapy in patients with lupus nephritis.
Researchers identified criteria and non-criteria features associated with SLE, which can be used in classification criteria.
Adding belimumab to standard therapy for lupus nephritis is associated with better renal outcomes compared with standard therapy alone.
An investigational type 1 interferon receptor inhibitor was associated with significant reduction in disease activity in patients with systemic lupus erythematosus.
Study findings from EULAR 2020 suggest that higher albumin levels provide a potentially protective effect on mental health in juvenile SLE.
Converting genotype information into an interpretable probability value for five different inflammatory arthritis-causing diseases could potentially improve the diagnostic efficiency of rheumatic disease.
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
